Related references
Note: Only part of the references are listed.Galectin-3 mediates cardiac remodeling caused by impaired glucose and lipid metabolism through inhibiting two pathways of activating Akt
Zhen Sun et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2021)
Biomarker profiling for risk of future heart failure (HFpEF) development
Chris J. Watson et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study
Tobias Daniel Trippel et al.
ESC HEART FAILURE (2021)
Identification of Galectin-3 as Potential Biomarkers for Renal Fibrosis by RNA-Sequencing and Clinicopathologic Findings of Kidney Biopsy
Shuo-Ming Ou et al.
FRONTIERS IN MEDICINE (2021)
Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction Understanding Mechanisms by Using Noninvasive Methods
Masaru Obokata et al.
JACC-CARDIOVASCULAR IMAGING (2020)
Circulating galectin-3 on admission and prognosis in acute heart failure patients: a meta-analysis
Hongsen Chen et al.
HEART FAILURE REVIEWS (2020)
Evaluation and management of heart failure with preserved ejection fraction
Barry A. Borlaug
NATURE REVIEWS CARDIOLOGY (2020)
Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction
Jyothirmayi Kanukurti et al.
JOURNAL OF LABORATORY PHYSICIANS (2020)
Heart Failure With Preserved Ejection Fraction Infrequently Evolves Toward a Reduced Phenotype in Long-Term Survivors A Long-Term Prospective Longitudinal Study
Josep Lupon et al.
CIRCULATION-HEART FAILURE (2019)
Heart Failure With Preserved Ejection Fraction In Perspective
Marc A. Pfeffer et al.
CIRCULATION RESEARCH (2019)
Association of Galectin-3 With Diabetes Mellitus in the Dallas Heart Study
Amy Vora et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association (vol 137, pg e67, 2018)
Benjamin
CIRCULATION (2018)
Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction
Uzair Ansari et al.
ANNALS OF LABORATORY MEDICINE (2018)
Galectin-3 in Heart Failure An Update of the Last 3 Years
Carolin Gehlken et al.
HEART FAILURE CLINICS (2018)
Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction
Rudolf A. de Boer et al.
JAMA CARDIOLOGY (2018)
Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction
Yameng Cui et al.
MEDICAL SCIENCE MONITOR (2018)
Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes
Anahita Ghorbani et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Heart Failure Stages Among Older Adults in the Community The Atherosclerosis Risk in Communities Study
[Anonymous]
CIRCULATION (2017)
Galectin-3 is an independent predictor of survival in systemic sclerosis
Reka Faludi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Epidemiology of heart failure with preserved ejection fraction
Shannon M. Dunlay et al.
NATURE REVIEWS CARDIOLOGY (2017)
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
Clyde W. Yancy et al.
CIRCULATION (2017)
Use of Biomarkers to Predict Readmission for Congestive Heart Failure
Sangita Sudharshan et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population
Tasnim F. Imran et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
Serial galectin-3 and future cardiovascular disease in the general population
A. Rogier van der Velde et al.
HEART (2016)
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
Sherif F. Nagueh et al.
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2016)
Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis
Stefano Menini et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2016)
How to diagnose heart failure with preserved ejection fraction: the value of invasive stress testing
A. E. Huis in 't Veld et al.
NETHERLANDS HEART JOURNAL (2016)
Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices
Cho-Kai Wu et al.
SCIENTIFIC REPORTS (2015)
Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial
Frank Edelmann et al.
EUROPEAN JOURNAL OF HEART FAILURE (2015)
Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study
Lori B. Daniels et al.
AMERICAN HEART JOURNAL (2014)
Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials
Wouter C. Meijers et al.
AMERICAN HEART JOURNAL (2014)
Plasma galectin 3 and heart failure risk in the Physicians' Health Study
Luc Djousse et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure
Tariq Ahmad et al.
JACC-HEART FAILURE (2014)
Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis
Lili Yu et al.
CIRCULATION-HEART FAILURE (2013)
Forecasting the Impact of Heart Failure in the United States A Policy Statement From the American Heart Association
Paul A. Heidenreich et al.
CIRCULATION-HEART FAILURE (2013)
Galectin-3 in heart failure with preserved ejection fraction
Rudolf A. de Boer et al.
EUROPEAN JOURNAL OF HEART FAILURE (2013)
Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT
Inder S. Anand et al.
EUROPEAN JOURNAL OF HEART FAILURE (2013)
How do patients with heart failure with preserved ejection fraction die?
Michelle M. Y. Chan et al.
EUROPEAN JOURNAL OF HEART FAILURE (2013)
Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction
Francisco Javier Carrasco-Sanchez et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Relationship of Plasma Galectin-3 to Renal Function in Patients With Heart Failure: Effects of Clinical Status, Pathophysiology of Heart Failure, and Presence or Absence of Heart Failure (September, e000760, 2012)
Gopal
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22
E. Wilson Grandin et al.
CLINICAL CHEMISTRY (2012)
The fibrosis marker galectin-3 and outcome in the general population
R. A. de Boer et al.
JOURNAL OF INTERNAL MEDICINE (2012)
Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community
Jennifer E. Ho et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function
Josef Wanninger et al.
CYTOKINE (2011)
Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study
Dirk J. A. Lok et al.
CLINICAL RESEARCH IN CARDIOLOGY (2010)
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin
Yun-He Liu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2009)
The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients
Yen-Hung Lin et al.
CLINICA CHIMICA ACTA (2009)
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction
UC Sharma et al.
CIRCULATION (2004)
Importance of heart failure with preserved systolic function in patients ≥65 years at age
DW Kitzman et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
Share Paper
